Quaggin Susan E 4

What Happened

Susan E. Quaggin, a director of AbbVie Inc., was granted 71 stock-equivalent units (reported as a derivative award) on March 31, 2026. The units are reported at $217.49 each, for a total reported value of $15,442. This was an award of director compensation (not an open-market purchase or sale).

Key Details

• Transaction date and type: 2026-03-31 — Grant/award (derivative acquisition) of 71 units.
• Price/value: $217.49 per unit; total value $15,442.
• Shares owned after transaction: Not specified in the filing excerpt.
• Filing date/timeliness: Form 4 filed 2026-04-02 — appears to be filed timely.
• Footnotes:
  • F1 — Director fees credited to a stock-equivalent unit account under a grantor trust and paid in cash generally at age 65 or upon retirement; units earn the same return as if fees were invested in AbbVie stock.
  • F2 — Balance includes stock-equivalent units acquired through a dividend reinvestment feature.

Context

This transaction reflects routine director compensation credited as stock-equivalent units (a derivative award), which are tracked like AbbVie shares but are intended to be paid in cash later under the trust arrangement. Such awards are standard board compensation and do not necessarily indicate a director’s personal buy/sell sentiment.